Compare Dollar General Corp. (DG) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Davita Inc — how do they compare? Dollar General Corp. trades at $124.27 (market cap $26.95B), while Davita Inc trades at $175.04 (market cap $11.28B). The key difference: Dollar General Corp. is far larger — about 2.4× Davita Inc's market cap, and Dollar General Corp. pays a 1.93% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Davita Inc for 113 Days on average.
| DG | DVA | |
|---|---|---|
Market Cap | $26.95B | $11.28B |
Volume | 1,654,929 | 650,294 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $240.96 |
52-Week Low | $95.94 | $103.87 |
Typical Hold Time | 59 Days | 113 Days |
Enterprise Value | $41.13B | $24.00B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $124.27, up 0.82% on the day, with a neutral technical signal and bearish moving average trend. The stock shows strong valuation metrics with a P/E of 15.86 and P/S of 0.62, while recent earnings have consistently beaten estimates. Revenue growth is steady, reaching $40.61 billion in 2025, though net income margin has compressed to 2.77%. Positive news includes tariff refunds boosting margins and expansion of same-day delivery via Instacart.
The outlook is cautiously optimistic, supported by analyst consensus price target of $137.27 (10.5% upside) and a 55.77% buy rating. Key opportunities include margin recovery initiatives and digital growth, while risks involve competitive pressures and consumer spending volatility. The stock presents a value opportunity with upside potential if execution improves.
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
